SCHEMBL23948252

SCHEMBL23948252

COc1ccc(Nc2ncc3c(n2)n(C2CCCCC2)c(=O)n3C)c(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 19/20 1.00
TTK P33981 4/20 0.98
CSF1R P07333 3/20 0.98
PIK3CA P42336 6/20 0.69
MTOR P42345 3/20 0.69
PIK3CD O00329 1/20 0.69
PIK3CB P42338 1/20 0.69
MAPK9 P45984 1/20 0.69
PIK3CG P48736 1/20 0.69
MAPK10 P53779 1/20 0.69
ATM Q13315 1/20 0.69
AURKA O14965 2/20 0.67
CCNA2 P20248 1/20 0.67
CDK2 P24941 1/20 0.67
KCNH2 Q12809 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29502021 1.00 PRKDC (1.00) PRKDCTTKCSF1RPIK3CAMTOR
SCHEMBL26159599 0.91 PRKDC (0.84) PRKDCTTKCSF1RPIK3CAMTOR
SCHEMBL25057401 0.85 PRKDC (0.74) PRKDCTTKCSF1RPIK3CAMTOR
SCHEMBL1781001 0.83 PRKDC (0.73) PRKDCTTKCSF1RPIK3CAMTOR
SCHEMBL24270848 0.82 PRKDC (1.00) PRKDCCSF1RPIK3CAMTORPIK3CD
SCHEMBL29492669 0.82 PRKDC (1.00) PRKDCCSF1RPIK3CAMTORPIK3CD
SCHEMBL29376473 0.81 TTK (1.00) PRKDCTTKCSF1RPIK3CAAURKA
SCHEMBL1782786 0.81 TTK (1.00) PRKDCTTKCSF1RPIK3CAAURKA
SCHEMBL26160047 0.80 PRKDC (0.75) PRKDCTTKCSF1RPIK3CAMTOR
SCHEMBL1782653 0.80 TTK (0.92) PRKDCTTKCSF1RPIK3CAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 PRKDC 316/4885TTK 1365/4885CSF1R 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.